Cargando…
The Course of SARS-COV2 Infection Was Not Severe in a Crohn’s Patient Who Administered Maintenance Anti-TNF Therapy Overlapping the Early Pre-Symptomatic Period of Infection
The Inflammatory Bowel Disease (IBD) population, which may require treatment with immunosuppressive medications, may be uniquely vulnerable to COVID-19 infection. In fact, there is some evidence these medications may inhibit the cytokine storm that is theorized to cause a rapid decline seen in COVID...
Autores principales: | Okeke, Francis, Mone, Anjali, Swaminath, Arun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7551561/ https://www.ncbi.nlm.nih.gov/pubmed/32824122 http://dx.doi.org/10.3390/antib9030042 |
Ejemplares similares
-
Review of inflammatory bowel disease and COVID-19
por: Sultan, Keith, et al.
Publicado: (2020) -
Fatigue in Inflammatory Bowel Diseases: Etiologies and Management
por: Nocerino, Angelica, et al.
Publicado: (2019) -
Ideal Vial Size for Infliximab in the Treatment of Inflammatory Bowel Disease: An Analysis of Pharmaceutical Waste and Physician Opinions
por: Schachne, Jonathan M, et al.
Publicado: (2021) -
Cannabis Use and Its Association With Thirty- and Ninety-Day Hospital Readmissions for Patients Admitted for an Inflammatory Bowel Disease Exacerbation
por: Oseni, Ellen A., et al.
Publicado: (2023) -
Anti-TNF Therapy in Crohn’s Disease
por: Adegbola, Samuel O., et al.
Publicado: (2018)